Altimmune (NASDAQ:ALT) Stock Moved Down to Strong Sell by Wall Street Zen

Wall Street Zen downgraded shares of Altimmune (NASDAQ:ALT) from a sell rating to a strong sell rating in a research report released on Saturday morning,Wall Street Zen reports.

Other equities analysts have also recently issued reports about the company. Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a research report on Friday. Evercore reaffirmed an “outperform” rating on shares of Altimmune in a research report on Wednesday, September 23rd. HC Wainwright reiterated a “buy” rating on shares of Altimmune in a report on Tuesday, July 28th. B. Riley Financial reissued a “buy” rating on shares of Altimmune in a research report on Friday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a research note on Monday, September 21st. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $14.33.

Altimmune Trading Up 2.2%

Shares of ALT traded up $0.04 during mid-day trading on Friday, hitting $1.65. 3,528,857 shares of the company’s stock traded hands, compared to its average volume of 3,885,901. The company has a quick ratio of 26.78, a current ratio of 26.78 and a debt-to-equity ratio of 0.07. Altimmune has a 1 year low of $1.58 and a 1 year high of $6.44. The firm has a market capitalization of $319.99 million, a P/E ratio of -2.28 and a beta of 0.16. The business’s 50-day moving average price is $2.58 and its 200-day moving average price is $3.15.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). As a group, sell-side analysts forecast that Altimmune will post -0.58 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Jerome Durso acquired 30,700 shares of Altimmune stock in a transaction that occurred on Friday, November 13th. The stock was bought at an average price of $1.62 per share, for a total transaction of $49,734.00. Following the completion of the transaction, the chief executive officer owned 93,200 shares in the company, valued at $150,984. The trade was a 49.12% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders acquired a total of 50,700 shares of company stock worth $82,334 in the last three months. 1.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Altimmune

Hedge funds and other institutional investors have recently made changes to their positions in the business. Nantahala Capital Management LLC boosted its holdings in shares of Altimmune by 14.7% in the third quarter. Nantahala Capital Management LLC now owns 1,720,000 shares of the company’s stock worth $4,919,000 after buying an additional 220,000 shares during the last quarter. R Squared Ltd increased its holdings in Altimmune by 99.6% during the third quarter. R Squared Ltd now owns 26,475 shares of the company’s stock valued at $76,000 after buying an additional 13,211 shares during the last quarter. StoneX Group Inc. purchased a new stake in Altimmune during the third quarter valued at approximately $46,000. Parallel Advisors LLC raised its position in Altimmune by 21,755.0% in the third quarter. Parallel Advisors LLC now owns 8,742 shares of the company’s stock worth $25,000 after acquiring an additional 8,702 shares during the period. Finally, Alps Advisors Inc. raised its position in Altimmune by 29.6% in the third quarter. Alps Advisors Inc. now owns 255,875 shares of the company’s stock worth $732,000 after acquiring an additional 58,501 shares during the period. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Trending Headlines about Altimmune

These are some of the ALT headlines that stood out recently:

• Positive Sentiment: Newly published 48-week Phase 2b IMPACT results showed pemvidutide improved non-invasive measures of liver fat, inflammation, and fibrosis, alongside weight loss and generally favorable tolerability. The findings support the ongoing Phase 3 PERFORMA MASH trial, though pemvidutide remains investigational. Trial results article
• Neutral Sentiment: B. Riley reaffirmed its Buy rating, providing supportive analyst sentiment, although the rating is not a guarantee of future performance.
• Negative Sentiment: Third-quarter loss per share was $0.15, wider than the $0.13 loss analysts expected. Higher research and development spending contributed to the miss, and commentary has raised concerns about the company’s capital needs despite its current cash runway. Earnings analysis

Altimmune Company Profile

Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.